Tianjin Chase Sun Pharmaceutical Gets Nod to Trial Nafamostat Mesylate for Injection

MT Newswires Live

02/06

Tianjin Chase Sun Pharmaceutical (SHE:300026) received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.

The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.

The pharmaceutical company's shares rose less than 3% at the close.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2609569846"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609569846\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609569846?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 17:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609569846","market":"fut","top_or_hot":-1,"title":"Tianjin Chase Sun Pharmaceutical Gets Nod to Trial Nafamostat Mesylate for Injection","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/300026\">Tianjin Chase Sun</a> Pharmaceutical (SHE:300026) received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.</p><p>The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.</p><p>The pharmaceutical company's shares rose less than 3% at the close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Chase Sun Pharmaceutical Gets Nod to Trial Nafamostat Mesylate for Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Chase Sun Pharmaceutical Gets Nod to Trial Nafamostat Mesylate for Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-06 17:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/300026\">Tianjin Chase Sun</a> Pharmaceutical (SHE:300026) received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.</p><p>The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.</p><p>The pharmaceutical company's shares rose less than 3% at the close.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"質押式回購","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609569846","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609569846","pubTimestamp":1770370777,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjin Chase Sun Pharmaceutical  received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.The pharmaceutical company's shares rose less than 3% at the close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300026":"红日药业","BK0077":"质押式回购","BK4109":"特种化学制品","BK0239":"医药制造","BK0188":"融资融券","CCF":"Chase Corp"},"translate_title":"天津大通太阳药业获批注射用甲磺酸萘莫司他试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300026":0.9,"CCF":1.5},"content_text":"Tianjin Chase Sun Pharmaceutical (SHE:300026) received approval from China's National Medical Products Administration for the clinical trials of nafamostat mesylate for injection, according to a Friday disclosure on the Shenzhen bourse.The drug is used to prevent coagulation of perfused blood during extracorporeal circulation, such as hemodialysis and plasma exchange.The pharmaceutical company's shares rose less than 3% at the close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}